Novavax Inc NVAX
We take great care to ensure that the data presented and summarized in this overview for NOVAVAX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVAX
View all-
Vanguard Group Inc Valley Forge, PA15.7MShares$110 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$82.9 Million0.0% of portfolio
-
Shah Capital Management11.1MShares$78 Million35.54% of portfolio
-
State Street Corp Boston, MA7.7MShares$53.9 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.79MShares$40.5 Million0.04% of portfolio
-
Morgan Stanley New York, NY4.94MShares$34.6 Million0.0% of portfolio
-
Ubs Group Ag4.85MShares$34 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.66MShares$25.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT2MShares$14 Million0.71% of portfolio
-
Northern Trust Corp Chicago, IL1.45MShares$10.2 Million0.0% of portfolio
Latest Institutional Activity in NVAX
Top Purchases
Top Sells
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at NVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2025
|
James Patrick Kelly EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,904
-7.86%
|
$47,232
$8.34 P/Share
|
|
Mar 07
2025
|
James Patrick Kelly EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,223
+13.99%
|
-
|
|
Mar 07
2025
|
John Trizzino President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,954
-17.01%
|
$111,632
$8.34 P/Share
|
|
Mar 07
2025
|
John Trizzino President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,890
+26.05%
|
-
|
|
Mar 01
2025
|
Mark J Casey EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,214
-3.66%
|
$9,712
$8.33 P/Share
|
|
Mar 01
2025
|
Mark J Casey EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+10.76%
|
-
|
|
Mar 01
2025
|
John Trizzino President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,185
-30.38%
|
$185,480
$8.33 P/Share
|
|
Mar 01
2025
|
John Trizzino President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,000
+38.61%
|
-
|
|
Mar 01
2025
|
John C Jacobs President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
38,451
-21.95%
|
$307,608
$8.33 P/Share
|
|
Mar 01
2025
|
John C Jacobs President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
83,334
+32.24%
|
-
|
|
Mar 01
2025
|
James Patrick Kelly EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,337
-31.05%
|
$226,696
$8.33 P/Share
|
|
Mar 01
2025
|
James Patrick Kelly EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,667
+39.13%
|
-
|
|
Mar 01
2025
|
Elaine O'Hara EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,344
-11.65%
|
$130,752
$8.33 P/Share
|
|
Mar 01
2025
|
Elaine O'Hara EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,600
+35.91%
|
-
|
|
Jan 23
2025
|
John C Jacobs President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
38,873
-29.74%
|
$349,857
$9.55 P/Share
|
|
Jan 23
2025
|
John C Jacobs President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
83,196
+38.89%
|
-
|
|
Dec 31
2024
|
Margaret G Mcglynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,178
+7.21%
|
$9,424
$8.61 P/Share
|
|
Dec 31
2024
|
Gregg H Alton Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,982
+9.73%
|
$15,856
$8.61 P/Share
|
|
Dec 31
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,906
-34.15%
|
$135,248
$8.04 P/Share
|
|
Dec 31
2024
|
James Patrick Kelly EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+41.42%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 542K shares |
|---|---|
| Grant, award, or other acquisition | 12.6K shares |
| Payment of exercise price or tax liability | 197K shares |
|---|---|
| Open market or private sale | 90.4K shares |